Trial · NCT01187888
Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy
NCT01187888, Phase 3, Terminated, Prof. Dr. Stefan Lorenzl
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy. Trials, record NCT01187888. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01187888
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy
- NCT number
- NCT01187888
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 44 participants, actual
- Lead sponsor
- Prof. Dr. Stefan Lorenzl
- Conditions
- Progressive Supranuclear Palsy
- Interventions
- Rasagiline, Sugar pill
- First posted
- 2010-08-24
- Last updated
- 2013-04-24
- Other registries' IDs
- eudract:2008-007520-26
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Assessment of the need for additional L-DOPA therapy or the need to increase the dose of L-DOPA during the trial | 1 year | Since there is no established treatment regimen for Progressive Supranuclear Palsy (PSP) patients, the only well characterized medication is L-3,4-Dihydroxyphenylalanine (L-DOPA) therapy. Since this therapy may exert a small effect in PSP patients, begin with L-DOPA therapy or increase in L-DOPA therapy will be used in this trial as rescue medication. |
| Primary | Reduction of the reported deterioration using the PSP rating scale | 1 year | To assess the efficacy of Rasagiline using the Progressive Supranuclear Palsy Rating Scale (PSPRS), aiming at a 33% reduction of the reported deterioration (Golbe et. al., 2007), i.e. a mean yearly increase of 6.5 instead of 9.7 points. |
| Secondary | Reduction of gait disturbances and postural stability | 1 year | |
| Secondary | Adverse Event (AE) incidence | 1 year | |
| Secondary | Safety laboratory values (blood cell count, aspartate aminotransferase [AST], alanine aminotransferase [ALT], creatinine, Vitamin B12, folic acid, homocysteine and methylmalonic acid) | 1 year | |
| Secondary | Vital signs | 1 year | |
| Secondary | Number of subjects (%) who discontinue the study | 1 year | |
| Secondary | Number of subjects (%) who discontinue the study due to AEs | 1 year |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01187888
GET https://conductscience.org/api/trials/v1/NCT01187888/registered